

ASX Announcement

1 September 2025

Appointment of Company Secretary

Global medical device company OncoSil Medical Limited (ASX:OSL) (“OncoSil Medical” or “the Company”) is pleased to announce the joint appointment of Mr Tim Luscombe and Mr David Wood as Joint Company Secretaries, effective 1 September 2025.

Tim and David are part of Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced company secretarial, CFO and transaction advisory solutions to the Healthcare sector. They bring strong expertise in financial management and corporate governance, drawing from their experiences providing these services to various ASX-listed, public unlisted, and private Healthcare companies.

OncoSil Medical advises Ms Olga Smejkalova from Acclime Australia has resigned as Company Secretary, effective 1 September 2025. The Board thanks Ms Olga Smejkalova and Acclime for their valuable contribution to the Company and wishes them well in their future endeavours.

Mr Tim Luscombe will now be the person responsible for communications between OncoSil Medical and the ASX regarding ASX Listing Rule matters.

Authorisation & Additional Information

This announcement was authorised by the Board of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>